# Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

Study · id `cardio:ct-nct01975818` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01975818](<https://clinicaltrials.gov/study/NCT01975818>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01975818

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 201 participants.

## Technical summary

Registry record NCT01975818. Randomized; no masking; primary purpose treatment. Start 2013-10-28 (actual); primary completion 2015-10-23 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 201 participants (enrolled count; ClinicalTrials.gov record NCT01975818, source copy `cardio:ctgov-nct01975818-2019-09-20`, retrieved 2026-10-26)
- Started: 2013-10-28 (actual) (ClinicalTrials.gov record NCT01975818, source copy `cardio:ctgov-nct01975818-2019-09-20`, retrieved 2026-10-26)
- Primary completion: 2015-10-23 (actual) (ClinicalTrials.gov record NCT01975818, source copy `cardio:ctgov-nct01975818-2019-09-20`, retrieved 2026-10-26)
- Completion: 2015-12-15 (actual) (ClinicalTrials.gov record NCT01975818, source copy `cardio:ctgov-nct01975818-2019-09-20`, retrieved 2026-10-26)
- Countries: United States; Japan (ClinicalTrials.gov record NCT01975818, source copy `cardio:ctgov-nct01975818-2019-09-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01975818-2019-09-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
- Acronym: DIALOGUE4
- Condition: Anemia
- Condition: Renal Insufficiency, Chronic
- Intervention (Drug): Molidustat (BAY 85-3934)
- Intervention (Biological): Epoetin alfa/beta
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

## Provenance

Content hash: 1e5a2f77e0a593f5f060e6937f35e36e887cc5f4d7cb3c13ad3b447c7d7c7355
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
